Kevin Harrod, Ph.D.

Despite the rapid deployment of vaccines that offer protective immunity, immunizations will not eradicate SARS-CoV-2, and break through infections will occur. Thus, therapeutic interventions and particularly antivirals will be critical in the postimmunization era of COVID-19. This application will use a high throughput drug screening platform to identify and repurpose already FDA approved drugs that may interfere with normal viral replication and could be used to blunt viral infections of the lung.